Can avatrombopag (Avatrombopag, Sucoxin) be used with immunity?

Avatrombopag/Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), mainly used to treat chronic immune thrombocytopenia (ITP) and thrombocytopenia in patients with chronic liver disease. In recent years, with in-depth research on its mechanism of action and clinical application, more and more doctors and researchers have begun to pay attention to the combined use of avatrombopag and immunotherapy. This article explores whether avatrombopag can be combined with immunotherapy, specifically in conditions such as chronic immune thrombocytopenia and aplastic anemia.

Avatrombopag promotes platelet production by promoting megakaryocytes in the bone marrow, and its mechanism is similar to otherTPO-RAs, such as Eltrombopag. In patients with chronic immune thrombocytopenia (ITP), avatrombopag not only increases platelet levels but may also improve patients' quality of life and safety to a certain extent. However, the treatment of ITP usually includes immunosuppressive therapy, such as glucocorticoids, intravenous immune globulin (IVIG), etc. Therefore, the combined use of avatropopag and immunotherapy is particularly important in these patients.

Theoretically, avatrombopag can further promote hematopoietic function on the basis of adequate immunosuppressive treatment. Because of avatrombopag's effects on megakaryocytes, it has been hypothesized that it may help achieve faster platelet recovery in patients receiving immunosuppressive therapy. However, current research on the specific synergistic effects between avatrombopag and immunotherapy is still limited. Many doctors choose to combine avatrombopag with immunosuppressive drugs in clinical practice, but there is a lack of support from large-scale clinical trials.

The potential use of avatrombopag in patients with aplastic anemia is also worthy of attention. These patients often require immunosuppressive therapy (IST) to control the autoimmune response. The addition of avatrombopag to IST may help further improve the speed and intensity of hematological response, thereby improving the patient's systemic condition. However, there is currently no conclusive evidence that this combination significantly improves efficacy. Therefore, although the combination of avatrombopag and immunotherapy is theoretically feasible, the reliability of the clinical effect still needs to be verified through more studies.

When using avatrombopag, doctors also need to pay special attention to its side effects. Most patients tolerate avatrombopag well, but in some cases, adverse reactions such as abnormal liver function and thrombosis may occur. When combining immunotherapy, the patient's overall health and potential risks need to be considered. Especially in patients taking immunosuppressive drugs, monitoring platelet levels and related indicators is critical to prevent the development of blood clots or other complications.

Reference materials:https://ashpublications.org/blood/article/142/Supplement%201/4091/500545/Avatrombopag-in-Combination-with-Immunosuppressive